PDL BioPharma to Present at the 4th Annual Credit Suisse Small/Mid Cap Conference

INCLINE VILLAGE, Nev., Sept. 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 4^th Annual Credit Suisse Small/Mid Cap Conference in New York City on Tuesday, September 17, 2013. Presentations at this conference will not be available via webcast.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.